Pulmonx Corporation (LUNG) vs Sera Prognostics, Inc. (SERA)
Pulmonx Corporation and Sera Prognostics, Inc. are both Medical Devices companies. Pulmonx Corporation and Sera Prognostics, Inc. are of similar size ($83.2M and $81.6M). Pulmonx Corporation grew revenue faster over the last twelve months: −3.43% against −35.2%. Pulmonx Corporation has the higher net margin (−55.0% vs −47,475.7%) and the higher return on invested capital (−141.0% vs −180.2%). Across the 18 metrics below, Pulmonx Corporation leads on 10 and Sera Prognostics, Inc. on 8.
Valuation
Profitability
| Metric | LUNG | SERA | Medical Devices median |
|---|---|---|---|
| Gross margin | 77.06% | (150.00%) | 56.01% |
| Operating margin | (52.96%) | (53,282.86%) | (15.03%) |
| Net margin | (55.03%) | (47,475.71%) | (20.40%) |
| Free cash flow margin | (35.07%) | (40,760.00%) | (7.24%) |
| Return on equity | (88.87%) | (45.03%) | (15.32%) |
| Return on assets | (36.74%) | (33.47%) | (19.72%) |
| Return on invested capital | (141.03%) | (180.22%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack